Printer Friendly

AXONYX COMPLETES SAFETY TRIAL FOR ITS LEAD ALZHEIMER'S DRUG.

Axonyx Inc. (NASDAQ:AXYX), New York, has reported successful results from a multiple dose Phase I human safety trial for Phenserine, the company's lead drug for Alzheimer's Disease.

In this study, which follows the company's successful single dose Phase I trial, the company identified a therapeutic range for the oral administration of multiple doses of the drug. This second Phase I trial confirmed preclinical findings with Phenserine, demonstrated patient safety and showed a significant inhibition of red blood cell acetylcholinesterase. Inhibition of this enzyme in brain is associated with improvement of memory and cognition in patients with Alzheimer's Disease.

Phenserine is a highly selective, reversible acetylcholinesterase inhibitor which may offer an alternative to drugs currently marketed for Alzheimer's Disease. This drug is unique in its preferential distribution and retention in the brain while disappearing rapidly from the blood.

"These results confirm that Phenserine is a safe and well tolerated drug, and encourages us to start a Phase II proof-of-concept/efficacy trial in patients with Alzheimer's Disease. Axonyx intends to commence this Phase II trial before the end of the year with completion expected during 2001," commented Marvin S. Hausman, M.D., Axonyx's president and CEO.

Axonyx Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders.

For more information, call 212/688-4770 or visit http://www.axonyx.com.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Oct 1, 2000
Words:240
Previous Article:"PRODUCT R" INHIBITS GROWTH OF ADENOVIRUS.
Next Article:ENCAP DEVELOPING LARVICIDE AGAINST WEST NILE VIRUS.


Related Articles
AXONYX INITIATES PHASE I CLINICAL TRIAL FOR PHENSERINE.
AXONYX REPORTS PROMISING RESULTS FROM PHENSERINE PHASE I TRIAL.
Axonyx Announces Positive Phase II Results for Phenserine in Alzheimer's Disease.
Axonyx Initiates Phase III Alzheimer's Disease Trial in Europe with Phenserine.
Axonyx to Present at Burrill's 15th Annual Life Sciences Partnering Meeting; Marvin S. Hausman, M.D., CEO of Axonyx, Featured Speaker.
Axonyx Expands Ongoing Phenserine Clinical Program.
Axonyx Initiates Second Phase III Alzheimer's Disease Trial with Phenserine.
Axonyx Announces Availability of Presentations on Phenserine from 7th International Conference on Alzheimer's and Parkinson's Disease on Corporate...
AXONYX REPORTS GOOD EFFECTS OF PHENSERINE ON ALZHEIMERS'.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters